BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 34957538)

  • 1. Model systems in SDHx-related pheochromocytoma/paraganglioma.
    Takács-Vellai K; Farkas Z; Ősz F; Stewart GW
    Cancer Metastasis Rev; 2021 Dec; 40(4):1177-1201. PubMed ID: 34957538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127).
    Gupta S; Zhang J; Milosevic D; Mills JR; Grebe SK; Smith SC; Erickson LA
    Endocr Pathol; 2017 Sep; 28(3):253-268. PubMed ID: 28646318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of metastatic pheochromocytoma and paraganglioma in
    Lee H; Jeong S; Yu Y; Kang J; Sun H; Rhee JK; Kim YH
    J Med Genet; 2020 Apr; 57(4):217-225. PubMed ID: 31649053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Succinate/Fumarate Ratio in Patients With Paraganglioma/Pheochromocytoma Attending an Endocrine Oncogenetic Unit.
    Bancel LP; Masso V; Dessein AF; Aubert S; Leteurtre E; Coppin L; Odou MF; Cao CD; Cardot-Bauters C; Pigny P
    J Clin Endocrinol Metab; 2023 Aug; 108(9):2343-2352. PubMed ID: 36848172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased expression of Nrf2 and elevated glucose uptake in pheochromocytoma and paraganglioma with SDHB gene mutation.
    Kamai T; Murakami S; Arai K; Nishihara D; Uematsu T; Ishida K; Kijima T
    BMC Cancer; 2022 Mar; 22(1):289. PubMed ID: 35300626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Succinate: A Serum Biomarker of SDHB-Mutated Paragangliomas and Pheochromocytomas.
    Lamy C; Tissot H; Faron M; Baudin E; Lamartina L; Pradon C; Al Ghuzlan A; Leboulleux S; Perfettini JL; Paci A; Hadoux J; Broutin S
    J Clin Endocrinol Metab; 2022 Sep; 107(10):2801-2810. PubMed ID: 35948272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
    Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
    Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline SUCLG2 Variants in Patients With Pheochromocytoma and Paraganglioma.
    Hadrava Vanova K; Pang Y; Krobova L; Kraus M; Nahacka Z; Boukalova S; Pack SD; Zobalova R; Zhu J; Huynh TT; Jochmanova I; Uher O; Hubackova S; Dvorakova S; Garrett TJ; Ghayee HK; Wu X; Schuster B; Knapp PE; Frysak Z; Hartmann I; Nilubol N; Cerny J; Taieb D; Rohlena J; Neuzil J; Yang C; Pacak K
    J Natl Cancer Inst; 2022 Jan; 114(1):130-138. PubMed ID: 34415331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of the oncometabolite succinate in SDHx-mutation carriers.
    Eijkelenkamp K; Osinga TE; Links TP; van der Horst-Schrivers ANA
    Clin Genet; 2020 Jan; 97(1):39-53. PubMed ID: 30977114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 15 YEARS OF PARAGANGLIOMA: Genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations.
    Baysal BE; Maher ER
    Endocr Relat Cancer; 2015 Aug; 22(4):T71-82. PubMed ID: 26113606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline mutations and genotype-phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea.
    Kim JH; Seong MW; Lee KE; Choi HJ; Ku EJ; Bae JH; Park SS; Choi SH; Kim SW; Shin C; Kim SY
    Clin Genet; 2014 Nov; 86(5):482-6. PubMed ID: 24134185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/- rats.
    Powers JF; Cochran B; Baleja JD; Sikes HD; Pattison AD; Zhang X; Lomakin I; Shepard-Barry A; Pacak K; Moon SJ; Langford TF; Stein KT; Tothill RW; Ouyang Y; Tischler AS
    Endocr Relat Cancer; 2020 Jun; 27(6):337-354. PubMed ID: 32252027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations.
    Jochmanova I; Wolf KI; King KS; Nambuba J; Wesley R; Martucci V; Raygada M; Adams KT; Prodanov T; Fojo AT; Lazurova I; Pacak K
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1421-1435. PubMed ID: 28374168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel SDHB and TMEM127 Mutations in Patients with Pheochromocytoma/Paraganglioma Syndrome.
    Patócs A; Lendvai NK; Butz H; Liko I; Sapi Z; Szucs N; Toth G; Grolmusz VK; Igaz P; Toth M; Rácz K
    Pathol Oncol Res; 2016 Oct; 22(4):673-9. PubMed ID: 26960314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation analysis of SDHB and SDHC: novel germline mutations in sporadic head and neck paraganglioma and familial paraganglioma and/or pheochromocytoma.
    Bayley JP; van Minderhout I; Weiss MM; Jansen JC; Oomen PH; Menko FH; Pasini B; Ferrando B; Wong N; Alpert LC; Williams R; Blair E; Devilee P; Taschner PE
    BMC Med Genet; 2006 Jan; 7():1. PubMed ID: 16405730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes.
    Udager AM; Magers MJ; Goerke DM; Vinco ML; Siddiqui J; Cao X; Lucas DR; Myers JL; Chinnaiyan AM; McHugh JB; Giordano TJ; Else T; Mehra R
    Hum Pathol; 2018 Jan; 71():47-54. PubMed ID: 29079178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.
    Richter S; Peitzsch M; Rapizzi E; Lenders JW; Qin N; de Cubas AA; Schiavi F; Rao JU; Beuschlein F; Quinkler M; Timmers HJ; Opocher G; Mannelli M; Pacak K; Robledo M; Eisenhofer G
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3903-11. PubMed ID: 25014000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study.
    Schovanek J; Martucci V; Wesley R; Fojo T; Del Rivero J; Huynh T; Adams K; Kebebew E; Frysak Z; Stratakis CA; Pacak K
    BMC Cancer; 2014 Jul; 14():523. PubMed ID: 25048685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour microenvironment in pheochromocytoma and paraganglioma.
    Martinelli S; Amore F; Canu L; Maggi M; Rapizzi E
    Front Endocrinol (Lausanne); 2023; 14():1137456. PubMed ID: 37033265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
    Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.